Commercial preparations and handling of botulinum toxin type A and type B

Clinics in Dermatology

Volumn 21, Issue 6, 2003, Pages 481-484

  Parish, Jennifer L ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; DILUENT; LIDOCAINE;

CLINICAL TRIAL; DILUTION; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DRUG STORAGE; DRUG SYNTHESIS; ESTHETICS; FREEZE DRYING; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRABISMUS;

EID: 0842283533     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2003.11.009     Document Type: Article

References (28)

1. Scott A.B. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology. 87:1980;1044-1049.
2. Aoki R.K. Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety. Toxicon. 40:2002;923-928.
3. Callaway J.E., Arezzo J.C., Grethlein A.J. Botulinum toxin type B an overview of its biochemistry and preclinical pharmacology . Semin Cutan Med Surg. 20:2001;127-136.
4. Matarasso S.L. Comparison of botulinum toxin types A and B a bilateral and double-blind randomized evaluation in the treatment of canthal rhytides . Dermatol Surg. 29:2003;7-13.
5. Klein A.W. Dilution and storage of botulinum toxin. Dermatol Surg. 24:1998;1179-1180.
6. Sloop R.R., Cole B.A., Escutin R.O. Reconstituted botulinum toxin type A does not lose potency in humans if it is refrozen or refrigerated for 2 weeks before use. Neurology. 48:1997;249-253.
7. Alam M., Dover J.S., Arndt K.A. Pain associated with injection of botulinum A exotoxin reconstituted using isotonic sodium chloride with and without preservative a double-blind, randomized controlled trial . Arch Dermatol. 138:2002;510-514.
8. Gassner H.G., Sherris D.A. Addition of an anesthetic agent to enhance the predictability of the effects of botulinum toxin type A injections a randomized controlled study . Mayo Clin Proc. 75:2000;701-704.
9. ® Cosmetic (botulinum toxin type A) purified neurotoxin complex. Irvine, CA: Allergan Inc.; 2002.
10. Package insert on Myobloc. San Diego, CA: Elan Pharmaceuticals; 2000.
11. Ramirez A.L., Reeck J., Maas C.S. Botulinum toxin type B (MyoBloc) in the management of hyperkinetic facial lines. Otolaryngol Head Neck Surg. 126:2002;459-467.
12. Cather J.C., Menter A. Update on botulinum toxin for facial aesthetics. Dermatol Clin. 20:2002;749-761.
13. Sadick N.S. Botulinum toxin type B for glabellar wrinkles a prospective open-label response study . Dermatol Surg. 28:2002;817-821.
14. Huang W., Foster J.A., Rogachefsky A.S. Pharmacology of botulinum toxin. J Am Acad Dermatol. 43:2000;249-259.
15. Package insert on Dysport. Berkshire, U.K.: Ipsen Ltd.; 2001.
16. Odergren T., Hjaltason H., Kaakkola S., et al. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry. 64:1998;6-12.
17. Nussgens Z., Roggenkamper P. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophthalmol. 235:1997;197-199.
18. Carruthers A., Carruthers J. Botulinum toxin type A history and current cosmetic use in the upper face . Semin Cutan Med Surg. 20:2001;71-84.
19. Sloop R.R., Cole B.A., Escutin R.O. Human response to botulinum toxin injection type B compared with type A . Neurology. 49:1997;189-194.
20. Matarasso A., Deva A.K. Botulinum toxin. Plast Reconstr Surg. 109:2002;1191-1197.
21. Setler P. The biochemistry of botulinum toxin type B. Neurology. 55:2000;S22-28.
22. Benedetto A.V. The cosmetic uses of botulinum toxin type A. Int J Dermatol. 38:1999;641-655.
23. Fulton J.E. Botulinum toxin the Newport Beach experience . Dermatol Surg. 24:1998;1219-1224.
24. Flynn T.C., Carruthers A., Carruthers J. Surgical pearl the use of the Ultra-Fine II short needle 0.3-cc insulin syringe for botulinum toxin injections . J Am Acad Dermatol. 46:2002;931-933.
25. Schwetz B.A. From the Food and Drug Administration. JAMA. 285:2001;724.
26. Ramirez A.L., Reeck J., Maas C.S. Preliminary experience with botulinum toxin type B in hyperkinetic facial lines. Plast Reconstr Surg. 109:2002;2154-2155.
27. Gartlan M.G., Hoffman H.T. Crystalline preparation of botulinum toxin type A (Botox) degradation in potency with storage . Otolaryngol Head Neck Surg. 108:1993;135-140.
28. Garcia A., Fulton J.E. Jr. Cosmetic denervation of the muscles of facial expression with botulinum toxin a dose-response study . Dermatol Surg. 22:1996;39-43.